Zealand Pharma AS (OCSE:ZEAL)
kr 730 0 (0%) Market Cap: 51.57 Bil Enterprise Value: 43.49 Bil PE Ratio: 0 PB Ratio: 5.83 GF Score: 67/100

Zealand Pharma A/S at Jefferies London Healthcare Conference Transcript

Nov 15, 2022 / 08:35AM GMT
Release Date Price: kr195 (+4.95%)
Peter Welford
Jefferies & Company - Analyst

Thank you all for joining us. For those who don't know me, my name is Peter Welford. I'm one of the European pharma and biotech analysts at Jefferies in London. It's my great pleasure to be moderating the next session in this track, which is Zealand Pharma. And it's a pleasure to have with us here today, so it seems like a long way away.

But that is Adam Steensberg, who's the CEO of Zealand Pharma. It's a fireside format. So if anyone has any questions in the audience, and it might cool you down, apologies for the temperature by cooling down, if you have some questions. If anyone has any questions, please do raise your hand, we'd love to get some questions from the audience.

Questions & Answers

Peter Welford
Jefferies & Company - Analyst

With that, let me kick off. So perhaps first of all, I guess it would probably make sense to just cover the sort of strategic changes that's happened in Zealand over the course of the last year or so. So could you just outline for us part, first of all,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot